These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 9859967)

  • 41. HIV Vaccine Trials: Ethical, Psychological, and Psychological-Social Aspects (1991-1996).
    Giami A; Linard F
    J Acquir Immune Defic Syndr; 2018 Oct; 79 Suppl 1():S51-S58. PubMed ID: 30222705
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Motivations to participate in a Phase I/II HIV vaccine trial: A descriptive study from Dar es Salaam, Tanzania.
    Tarimo EA; Bakari M; Kakoko DC; Kohi TW; Mhalu F; Sandstrom E; Kulane A
    BMC Public Health; 2016 Feb; 16():182. PubMed ID: 26911203
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Willingness to participate in HIV vaccine clinical trials among Chinese men who have sex with men.
    Li Q; Luo F; Zhou Z; Li S; Liu Y; Li D; Shi W; Raymond HF; Ruan Y; Shao Y
    Vaccine; 2010 Jun; 28(29):4638-43. PubMed ID: 20452428
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety profile of phase I and II preventive HIV type 1 envelope vaccination: experience of the NIAID AIDS Vaccine Evaluation Group.
    Keefer MC; Wolff M; Gorse GJ; Graham BS; Corey L; Clements-Mann ML; Verani-Ketter N; Erb S; Smith CM; Belshe RB; Wagner LJ; McElrath MJ; Schwartz DH; Fast P
    AIDS Res Hum Retroviruses; 1997 Sep; 13(14):1163-77. PubMed ID: 9310283
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Factors related to the willingness of young gay men to participate in preventive HIV vaccine trials.
    Hays RB; Kegeles SM
    J Acquir Immune Defic Syndr Hum Retrovirol; 1999 Feb; 20(2):164-71. PubMed ID: 10048904
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Required HIV antibody testing, social risk, and HIV-vaccine efficacy trials.
    MacQueen KM; Buchbinder SP; Douglas JM; Judson FN; McKirnan DJ; Bartholow BN
    AIDS Public Policy J; 1996; 11(2):104-12. PubMed ID: 10915243
    [No Abstract]   [Full Text] [Related]  

  • 47. Readiness of high-risk populations in the HIV Network for Prevention Trials to participate in HIV vaccine efficacy trials in the United States.
    Koblin BA; Heagerty P; Sheon A; Buchbinder S; Celum C; Douglas JM; Gross M; Marmor M; Mayer K; Metzger D; Seage G
    AIDS; 1998 May; 12(7):785-93. PubMed ID: 9619811
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pediatric HIV type 1 vaccine trial acceptability among mothers in Kenya.
    Farquhar C; John-Stewart GC; John FN; Kabura MN; Kiarie JN
    AIDS Res Hum Retroviruses; 2006 Jun; 22(6):491-5. PubMed ID: 16796522
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Gender aspects on HIV prevention efforts and participation in HIV vaccine trials among Police officers in Dar es Salaam, Tanzania.
    Tarimo EAM; Kakoko DCV; Kohi TW; Bakari M; Sandstrom E; Siyame D; Mhalu F; Kulane A
    BMC Public Health; 2018 Jul; 18(1):905. PubMed ID: 30031376
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Knowledge and attitudes regarding preventative HIV vaccine clinical trials in Italy: results of a national survey.
    Starace F; Wagner TM; Luzi AM; Cafaro L; Gallo P; Rezza G
    AIDS Care; 2006 Jan; 18(1):66-72. PubMed ID: 16282079
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Background morbidity in HIV vaccine trial participants from various geographic regions as assessed by unsolicited adverse events.
    Schmidt C; Smith C; Barin B; Bakhtyari A; Bart PA; Bekker LG; Chomba E; Clumeck N; Ho D; Hoosen A; Jaoko W; Kaleebu P; Karita E; Keefer MC; van Lunzen J; McMichael A; Mehendale S; Peters B; Ramanathan VD; Robinson A; Rockstroh J; Vardas E; Vets E; Weber J; Graham BS; Than S; Excler JL; Kochhar S; Ho M; Heald A; Fast PE
    Hum Vaccin Immunother; 2012 May; 8(5):630-8. PubMed ID: 22634443
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Future access to HIV vaccines. Report from a WHO-UNAIDS Consultation, Geneva, 2-3 October 2000.
    AIDS; 2001 May; 15(7):W27-44. PubMed ID: 11399975
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored Phase I and II clinical trials.
    Gilbert PB; Chiu YL; Allen M; Lawrence DN; Chapdu C; Israel H; Holman D; Keefer MC; Wolff M; Frey SE;
    Vaccine; 2003 Jun; 21(21-22):2933-47. PubMed ID: 12798637
    [TBL] [Abstract][Full Text] [Related]  

  • 54. HIV vaccine trial preparedness among Spanish-speaking Latinos in the US.
    Brooks RA; Newman PA; Duan N; Ortiz DJ
    AIDS Care; 2007 Jan; 19(1):52-8. PubMed ID: 17129857
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Therapeutic vaccine trails in Thailand.
    Churdboonchart V
    J HIV Ther; 2004 Sep; 9(3):57-9. PubMed ID: 15534562
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sexual risk behaviour of Canadian participants in the first efficacy trial of a preventive HIV-1 vaccine.
    Lampinen TM; Chan K; Remis RS; Merid MF; Rusch M; Vincelette J; Logue K; Popovic V; Alary M; Schechter MT; Hogg RS
    CMAJ; 2005 Feb; 172(4):479-83. PubMed ID: 15710939
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network.
    Belshe RB; Graham BS; Keefer MC; Gorse GJ; Wright P; Dolin R; Matthews T; Weinhold K; Bolognesi DP; Sposto R
    JAMA; 1994 Aug; 272(6):475-80. PubMed ID: 7913731
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Recruiting volunteers for a multisite phase I/II HIV preventive vaccine trial in Thailand.
    Thapinta D; Jenkins RA; Morgan PA; Chiu J; Boenim W; Bussaratid V; Chaddic C; Naksrisook S; Phonrat B; Sirijongdee N; Sornsathapornkul P; Sontirat A; Srisaengchai P; Suwanarach C; Wongkamhaeng S; Brown AE; Khamboonruang C; Nitayaphan S; Pitisuttithum P; Thongchareon P;
    J Acquir Immune Defic Syndr; 2002 Aug; 30(5):503-13. PubMed ID: 12154341
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluation of attitude, risk behavior and expectations among Thai participants in Phase I/II HIV/AIDS vaccine trials.
    Maek-A-Nantawat W; Pitisuttithum P; Phonrat B; Bussaratid V; Naksrisook S; Peonim W; Thantamnu N; Muanaum R
    J Med Assoc Thai; 2003 Apr; 86(4):299-307. PubMed ID: 12757073
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers.
    Belshe RB; Stevens C; Gorse GJ; Buchbinder S; Weinhold K; Sheppard H; Stablein D; Self S; McNamara J; Frey S; Flores J; Excler JL; Klein M; Habib RE; Duliege AM; Harro C; Corey L; Keefer M; Mulligan M; Wright P; Celum C; Judson F; Mayer K; McKirnan D; Marmor M; Woody G;
    J Infect Dis; 2001 May; 183(9):1343-52. PubMed ID: 11294665
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.